Literature DB >> 11001386

Anvirzel, an extract of Nerium oleander, induces cell death in human but not murine cancer cells.

S Pathak1, A S Multani, S Narayan, V Kumar, R A Newman.   

Abstract

The purpose of this study was to examine the mechanism(s) and differential cell-killing effects of Anvirzel, an extract of oleander (Nerium oleander; family-Apocynaceae), and its derivative compound Oleandrin on human, canine and murine tumor cells. Cells received different concentrations of Anvirzel (1.0 ng/ml to 500 microg/ml) or Oleandrin (0.01 ng/ml to 50 microg/ml) in both continuously treated and pulse-treated/recovery cultures. The cytotoxicity of these compounds was then determined. Both Anvirzel and Oleandrin were able to induce cell killing in human cancer cells, but not in murine cancer cells; the cell-killing potency of Oleandrin was greater than that of Anvirzel. Canine oral cancer cells treated with Anvirzel showed intermediate levels of response, with some abnormal metaphases and cell death resulting from the treatment. From these results we conclude that Anvirzel and Oleandrin act in a species-specific manner, and while testing the effectiveness of a new compound for cancer treatment, one must use not only murine but a variety of cancer cells, including those of human origin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001386     DOI: 10.1097/00001813-200007000-00006

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  20 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

2.  Modular Total Synthesis and Cell-Based Anticancer Activity Evaluation of Ouabagenin and Other Cardiotonic Steroids with Varying Degrees of Oxygenation.

Authors:  Hem Raj Khatri; Bijay Bhattarai; Will Kaplan; Zhongzheng Li; Marcus John Curtis Long; Yimon Aye; Pavel Nagorny
Journal:  J Am Chem Soc       Date:  2019-03-14       Impact factor: 15.419

3.  Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells.

Authors:  Yashin Sreenivasan; Pongali B Raghavendra; Sunil K Manna
Journal:  J Clin Immunol       Date:  2006-06-16       Impact factor: 8.317

4.  Phase 1 trial of Anvirzel in patients with refractory solid tumors.

Authors:  Tarek Mekhail; Hanspreet Kaur; Ram Ganapathi; G Thomas Budd; Paul Elson; Ronald M Bukowski
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

5.  Effective killing of leukemia cells by the natural product OSW-1 through disruption of cellular calcium homeostasis.

Authors:  Celia Garcia-Prieto; Kausar Begam Riaz Ahmed; Zhao Chen; Yan Zhou; Naima Hammoudi; Ying Kang; Changgang Lou; Yan Mei; Zhendong Jin; Peng Huang
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

6.  Cellular location and expression of Na+, K+ -ATPase α subunits affect the anti-proliferative activity of oleandrin.

Authors:  Peiying Yang; Carrie Cartwright; Ekem Efuet; Stanley R Hamilton; Ignacio Ivan Wistuba; David Menter; Crandell Addington; Imad Shureiqi; Robert A Newman
Journal:  Mol Carcinog       Date:  2012-10-16       Impact factor: 4.784

7.  Antiproliferative and phytochemical analyses of leaf extracts of ten Apocynaceae species.

Authors:  Siu Kuin Wong; Yau Yan Lim; Noor Rain Abdullah; Fariza Juliana Nordin
Journal:  Pharmacognosy Res       Date:  2011-04

8.  Digitoxin and its analogs as novel cancer therapeutics.

Authors:  Hosam A Elbaz; Todd A Stueckle; William Tse; Yon Rojanasakul; Cerasela Zoica Dinu
Journal:  Exp Hematol Oncol       Date:  2012-04-05

9.  Trial watch: Cardiac glycosides and cancer therapy.

Authors:  Laurie Menger; Erika Vacchelli; Oliver Kepp; Alexander Eggermont; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

10.  Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines.

Authors:  Panagiotis Apostolou; Maria Toloudi; Marina Chatziioannou; Eleni Ioannou; Dennis R Knocke; Joe Nester; Dimitrios Komiotis; Ioannis Papasotiriou
Journal:  BMC Pharmacol Toxicol       Date:  2013-03-25       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.